semaglutide success stories expert analysis My first year off GLPs | Story Why adherence determines weight loss

Oral Wegovy (semaglutide) has demonstrated a 15% weight-loss average in clinical trials, while Foundayo (orforglipron) has helped people lose approximately 12% to 14% of their starting weight

The trial escalation tables stepped the amount up on a monthly cadence, beginning in the low single-digit milligram range and only advancing once the prior level felt comfortable

Semaglutide has a 94% similarity to human GLP-1, which allows it to bind selectively to the GLP-1 receptor

doi: 10.1056/NEJMoa2107519 36 LudvikBGiorginoFJdarEFriasJPFernndez LandLBrownKet al

This distinction matters when evaluating a patients candidacy and setting expectations for the protocol